HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: A nested case-control study

American Journal of Transplantation

Volumn 15, Issue 1, 2015, Pages 137-148

  Sapir Pichhadze, R ^a,b,c,h   Tinckam, K ^a,c   Quach, K ^a,d   Logan, A G ^a,b,c   Laupacis, A ^b,e   John, R ^c   Beyene, J ^b,e,f   Kim, S J ^a,b,c,g  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; HLA DRB5 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA DQ EPLET MISMATCH; HLA DR EPLET MISMATCH; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOGENICITY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DUPLICATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRANSPLANT GLOMERULOPATHY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; COMPARATIVE STUDY; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROGNOSIS;

ADULT; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84919681541     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12968     Document Type: Article

References (88)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant 2014; 14: 11-44.
2. Kaplan B, Meier-Kriesche HU., Death after graft loss: An important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970-974.
3. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242.
4. Cosio FG, Gloor JM, Sethi S, Stegall MD., Transplant glomerulopathy. Am J Transplant 2008; 8: 492-496.
5. Husain S, Sis B., Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 2013; 62: 352-363.
6. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
7. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
8. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
9. Haas M., Transplant glomerulopathy: It's not always about chronic rejection. Kidney Int 2011; 80: 801-803.
10. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
11. Habib R, Broyer M., Clinical significance of allograft glomerulopathy. Kidney Int Suppl 1993; 43: S95-S98.
12. Sijpkens YW, Joosten SA, Wong MC, et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 2409-2418.
13. Suri DL, Tomlanovich SJ, Olson JL, Meyer TW., Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000; 35: 674-680.
14. Kim MG, Kim YJ, Kwon HY, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton) 2013; 18: 820-826.
15. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
16. Jordan SC, Reinsmoen N, Lai CH, Vo A., Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discov Med 2012; 13: 235-245.
17. Bartel G, Schwaiger E, Bohmig GA., Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142-1155.
18. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192-1194.
19. Gaston RS., Our evolving understanding of late kidney allograft failure. Current Opin Organ Transplant 2011; 16: 594-599.
20. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
21. Gilks WR, Bradley BA, Gore SM, Klouda PT., Substantial benefits of tissue matching in renal transplantation. Transplantation 1987; 43: 669-674.
22. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW., Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034-1040.
23. Eng HS, Bennett G, Chang SH, et al. Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Hum Immunol 2011; 72: 386-391.
24. Nair R, Fraer M, Agrawal N, Suneja M., Acute transplant glomerulopathy is associated with antibody-mediated rejection and poor graft outcome. Transplant Proc 2010; 42: 3507-3512.
25. Willicombe M, Brookes P, Sergeant R, et al. De-novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172-177.
26. Ting A, Morris PJ., Powerful effect of HL-DR matching on survival of cadaveric renal allografts. Lancet 1980; 2: 282-285.
27. Freedman BI, Thacker LR, Heise ER, Adams PL., HLA-DQ matching in cadaveric renal transplantation. Clin Transplant 1997; 11: 480-484.
28. Hsia S, Tong JY, Parris GL, et al. Molecular compatibility and renal graft survival-The HLA DRB1 genotyping. Transplantation 1993; 55: 395-399.
29. Colvin RB, Hirohashi T, Farris AB, Minnei F, Collins AB, Smith RN., Emerging role of B cells in chronic allograft dysfunction. Kidney Int Suppl 2010; 119: S13-S17.
30. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681-685.
31. Duquesnoy RJ., A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847-862.
32. Brooks EG, MacPherson BR, Fung MK., Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008; 48: 2159-2166.
33. Claas FH, Dankers MK, Oudshoorn M, et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005; 14: 187-191.
34. Duquesnoy RJ., " Match and treat": An effective strategy for transplanting highly sensitized pediatric transplant candidates ? Pediatr Transplant 2007; 11: 3-4.
35. Duquesnoy RJ, Marrari M., Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: A report of a collaborative study conducted during the 12th International Histocompatibility Workshop. Transplantation 1997; 63: 1743-1751.
36. Duquesnoy RJ, Askar M., HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007; 68: 12-25.
37. Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol 2008; 18: 352-360.
38. Duquesnoy RJ, Marrari M., Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens 2009; 74: 117-133.
39. Marrari M, Duquesnoy RJ., Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens. Tissue Antigens 2009; 74: 134-146.
40. Duquesnoy RJ, Marrari M., HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies. Curr Opin Organ Transplant 2009; 14: 403-409.
41. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de-novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114-3122.
42. Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ., Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int 2014; 85: 1404-1411.
43. Famure O, Phan N, Kim S., Health information management for research and quality assurance: The Comprehensive Renal Transplant Research Information System (CoReTRIS). Health Care Manage Forum 2014; 27: 30-36.
44. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
45. Rothman KJ, Greenland S, Lash TL., Modern epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008.
46. Cano P, Klitz W, Mack SJ, et al. Common and well-documented HLA alleles: Report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics. Hum Immunol 2007; 68: 392-417.
47. Tinckam K., Histocompatibility methods. Transplant Rev (Orlando) 2009; 23: 80-93.
48. Mack SJ, Cano P, Hollenbach JA, et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens 2013; 81: 194-203.
49. Cano P, Mack SJ, Fernandez-Vina M., The CWD allele catalog in China. Hum Immunol 2012; 73: 60.
50. Maiers M, Gragert L, Klitz W., High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007; 68: 779-788.
51. Robinson J, Waller MJ, Parham P, et al. IMGT/HLA and IMGT/MHC: Sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31: 311-314.
52. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR., Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913-D919.
53. Navarrete C, Jaraquemada D, Fainboim L, et al. Genetic and functional relationship of the HLA-DR and HLA-DQ antigens. Immunogenetics 1985; 21: 97-101.
54. Fernandez-Vina M, Moraes JR, Moraes ME, Miller S, Stastny P., HLA class II haplotypes in Amerindians and in black North and South Americans. Tissue Antigens 1991; 38: 235-237.
55. Fuggle SV, Carter C, Watts F, Kirkley J, Morris PJ., Monoclonal antibody definition of multiple polymorphic epitopes on human leukocyte antigen-DRw52. Hum Immunol 1987; 20: 249-264.
56. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference standards: High-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003; 62: 296-307.
57. Fernandez-Vina MA, Gao XJ, Moraes ME, et al. Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics 1991; 34: 299-312.
58. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG., Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008; 8: 48.
59. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
60. Haririan A, Fagoaga O, Daneshvar H, et al. Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant 2006; 20: 226-233.
61. Kosmoliaptsis V, Sharples LD, Chaudhry AN, Halsall DJ, Bradley JA, Taylor CJ., Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011; 91: 183-190.
62. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9: 1826-1834.
63. Iniotaki-Theodoraki AG, Boletis JN, Trigas G, Kalogeropoulou HG, Kostakis AG, Stavropoulos-Giokas CG., Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period. Transplantation 2003; 75: 1601-1603.
64. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS., The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117-1124.
65. Devos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604.
66. Kobayashi T, Maruya E, Niwa M, et al. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Hum Immunol 2011; 72: 11-17.
67. Tambur AR, Rosati J, Roitberg S, Glotz D, Friedewald JJ, Leventhal JR., Epitope analysis of HLA-DQ antigens: What does the antibody see ? Transplantation 2014; 98: 157-166.
68. Tambur AR, Claas FH., Toward HLA epitope matching in clinical transplantation. Am J Transplant 2013; 13: 3059-3060.
69. Haas M, Mirocha J., Early ultrastructural changes in renal allografts: Correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011; 11: 2123-2131.
70. Gebel HM, Bray RA, Nickerson P., Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.
71. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23: 2061-2071.
72. McKenna RM, Takemoto SK, Terasaki PI., Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
73. Wiebe C, Nickerson P., Posttransplant monitoring of de-novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013; 18: 470-477.
74. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de-novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
75. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192-1198.
76. Rosenberg WM, Bushell A, Higgins RM, et al. Isolated HLA-DP mismatches between donors and recipients do not influence the function or outcome of renal transplants. Hum Immunol 1992; 33: 5-9.
77. Pfeiffer K, Vogeler U, Albrecht KH, Eigler FW, Buchholz B, Grosse-Wilde H., HLA-DP antibodies in patients awaiting renal transplantation. Transpl Int 1995; 8: 180-184.
78. Qiu J, Cai J, Terasaki PI, El-Awar N, Lee JH., Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80: 1511-1513.
79. Perkowska-Ptasinska A, Ciszek M, Chmura A, Galazka Z, Paczek L, Durlik M., Transplant glomerulopathy: Clinical and pathological correlations. Transplant Proc 2009; 41: 141-149.
80. Kuypers DR, Vanrenterghem Y., Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: An open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004; 26: 1834-1844.
81. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y., Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18: 861-868.
82. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y., The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: Simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metab Dispos 2004; 32: 1421-1425.
83. van Gelder T., Drug interactions with tacrolimus. Drug Saf 2002; 25: 707-712.
84. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002; 34: 1733-1735.
85. Takahashi K, Yano I, Fukuhara Y, et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet 2007; 22: 441-444.
86. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharmacokinetic drug interactions: Effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009; 23: 137-145.
87. John R, Herzenberg AM., Our approach to a renal transplant biopsy. J Clin Pathol 2010; 63: 26-37.
88. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.